In this photo illustration, the logo of the British multinational pharmaceutical company GlaxoSmithKline (GSK) is displayed on a smartphone with a computer model of the COVID-19 coronavirus in the background.
Budrul Chukrut | Images SOPA | fake images
Britain’s GlaxoSmithKline and France’s Sanofi said on Monday they had started a new clinical trial of their protein-based Covid-19 vaccine candidate and aim to reach the final testing stage in the second quarter.
If the results are conclusive, the two drug companies hope to see the vaccine approved by the fourth quarter after initially targeting the first half of this year.
The move comes after drug makers said in December that their vaccine would be delayed after clinical trials showed insufficient immune responses in older people.
The new trial will aim to evaluate the safety, tolerability and immune response of the vaccine in 720 healthy adults in the United States, Honduras and Panama, the companies said.
Sanofi and the GSK candidate use the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines. It will be combined with an adjuvant, a substance that acts as an injection booster, manufactured by GSK.
The study will test two injections given 21 days apart.